Showing 1 – 20 of 1047
Relevance | Newest | Oldest |
  • JAMA June 27, 2017

    Figure: Hunt for an HIV Vaccine Intensifies

    Clinical trials testing broadly neutralizing antibodies (green) as a preventive vaccine against HIV (red) are currently under way.
  • JAMA December 13, 2016

    Figure: Flow Diagram for Primary Per-Protocol Immunogenicity Population Administered the 9-Valent Human Papillomavirus (HPV) Vaccine

    aFour (aged 9-14 years) were sexually active prior to enrollment; 4 unlikely to adhere to study procedures; 3 unable to give consent or assent; 2 had a history or current evidence of medical conditions that might interfere with the results of the study; 1 was judged to be in poor physical health; 1 had a history of abnormal Papanicolaou test results; and 1 had a history of severe allergic reaction.bOne participant discontinued the study after providing data for the analyses.cTo be included in the primary per-protocol immunogenicity population, individuals were required to (1) be seronegative at day 1 for the HPV type being analyzed; (2) receive all planned doses within acceptable day ranges; (3) have a serology result after the last dose within an acceptable day range; and (4) have no other protocol violations that could interfere with the evaluation of participant’s immune response to the study vaccine. Individuals included provided data for analysis of 1 or more HPV types.dThe total number of participants excluded from the primary analysis only counts a participant once. Individuals were counted once in each applicable exclusion subcategory, but a participant may appear in more than 1 subcategory. Additional data and information appear in eTable 1 in Supplement 2.
  • JAMA June 14, 2016

    Figure: Flowchart of Enrolled Participants and Progress Through the LIPS-A Trial

    Reasons for exclusion were not mutually exclusive and exhaustive because participants could have more than 1 reason for exclusion. Exclusion after randomization (n = 10) resulted in a change from an intention-to-treat analysis to a modified intention-to-treat analysis denoted as the full analysis set in International Conference on Harmonization statistical guidelines (E9 guidelines). The full analysis set was used for all analyses. The ineligibility reasons for the 4 participants withdrawn from the intention-to-treat sample were allergy to aspirin confirmed before first dose but after randomization; non-English speaking and removed per institutional review board determination; participant enrolled into study twice (second enrollment excluded); and patient was determined to have acute kidney injury after consent but prior to first dose. The 6 participants who withdrew consent indicated that previously collected data could not be used in the study.
  • JAMA June 16, 2015

    Figure: More Protection Against Plague

  • JAMA May 26, 2015

    Figure: High-Dose Novel Ebola Vaccine Immunogenic and Safe

    Recent findings suggest a novel Ebola vaccine is safe and immunogenic.
  • JAMA May 19, 2015

    Figure: Study Evaluates Shortened TB Drug Regimen

    A recent study suggests a shortened drug regimen holds promise in treating tuberculosis.
  • JAMA January 6, 2015

    Figure: Structural Analysis of Antibodies in Ebola Treatment

    Structural analysis of antibodies in the experimental Ebola treatment ZMapp reveals sites of viral vulnerability.
  • JAMA December 17, 2014

    Figure 1: Flow of Patients Through the Japanese Primary Prevention Project (JPPP)

    Data onpatients assessed for eligibility are not available.aProtocol violations (aspirin, n=19; no aspirin, n=22); delay in start of treatment (aspirin, n=10; no aspirin, n=15); unreported data by investigators in the clinics (aspirin, n=26; no aspirin, n=22).bReasons for not meeting inclusion criteria were serious blood abnormalities (aspirin, n = 2), history of prohibited drugs (aspirin, n = 12; no aspirin, n = 18), cerebrovascular disease (aspirin, n = 6; no aspirin, n = 7), atrial fibrillation (aspirin, n = 3), hypersensitivity to aspirin (aspirin, n = 3), peptic ulcer (aspirin, n = 2), atherosclerotic disease (aspirin, n = 1), or long-term use of nonsteroidal anti-inflammatory drugs (aspirin, n = 1).cClinic or investigator circumstances were closure of clinic and investigator death.
  • JAMA September 24, 2014

    Figure: FDA Warning: Phony Ebola Treatments Being Sold Online

    Some companies are selling fraudulent products online that they claim treat Ebola infection, the US Food and Drug Administration has warned.
  • JAMA June 18, 2014

    Figure: Lyme Disease Test Raises Concern

  • JAMA June 4, 2014

    Figure: Newly Isolated Antibodies May Block Deadly Respiratory Infection

    Two newly identified human neutralizing antibodies block cellular entry of Middle East respiratory syndrome coronavirus, which causes severe and often fatal acute respiratory illness.
  • JAMA July 10, 2013

    Figure 1: Participant Flow

    NYU indicates New York University; PSA, prostate-specific antigen.aExclusionary medical factors included recent or current history of anemia, iron deficiency problems or subclinical iron deficiency at baseline, diabetes or insulin resistance requiring use of medication, thyroid disease, significant renal impairment, need for a sodium-restricted diet, substantive tendency to be constipated (grade ≥2 experienced regularly), a medical problem precluding the consumption of soy or casein such as allergies to soy or milk protein, and postoperative PSA of 0.07 ng/mL or higher. Fifty-four patients had diabetes, 8 had thyroid disease, 4 had anemia or low iron status, 2 had other malignancies, 1 had renal disease, and 1 had mental disease.bThe 4-month postsurgery deadline had passed for these patients before pathology review could occur.cPreviously undetected exclusionary medical factors included 4 patients who had diabetes, 1 who had thyroid disease, 1 who had anemia, 2 who had protein allergies, 1 who had recurrent constipation, 1 who had a restricted diet, and 1 who had mental disease.dEight eligible participants were referred to the study by participating clinical sites other than NYU and the Manhattan VA; 1 eligible participant was referred to the study by a urologist in private practice. All 9 participants were confirmed to be at high risk by pathology review.eThe median time between surgery and randomization was identical in both groups (14 weeks; 95% CI, 13.1-14.1; range, 7 or 8 to 18 weeks).
  • Food, Skin Allergies Have Increased in US Children

    Abstract Full Text
    JAMA. 2013; 309(22):2319-2319. doi: 10.1001/jama.2013.6392
  • JAMA March 27, 2013

    Figure: Flow Diagram of Sublingual Immunotherapy Studies

    aArticles were excluded by 2 reviewers at this level so this number is exceeded by the total for all of the exclusions listed. bThe possible other reasons included control group is a healthy population, routes of administration not included (eg, oral, nasal, lymph node), abandoned interventions, outcomes not reported, no comparator group, continued medical education reports, editorials or reviews, studies about mechanism of action, other allergies (eg, food, aspirin), study in animals or in vitro, or fewer than 6 patients per treatment group.
  • QuickStats: Percentage of Children Aged ≤17 Years with Eczema or Any Kind of Skin Allergy, by Selected Races/Ethnicities—National Health Interview Survey, United States, 2000-2010

    Abstract Full Text
    JAMA. 2012; 307(10):1021-1021. doi:
  • JAMA January 25, 2012

    Figure: Treatment Rather Than Avoidance May Be Within Reach for Children With Food Allergies

    Scientists studying allergies to foods such as peanuts, tree nuts, milk, eggs, wheat, shellfish, and fish are investigating ways to induce tolerance to food allergens in affected individuals.
  • Unapproved Drugs Pulled

    Abstract Full Text
    JAMA. 2011; 305(16):1646-1646. doi: 10.1001/jama.2011.536
  • JAMA April 13, 2011

    Figure: Research Provides New Insights on How Hygiene Affects Asthma and Allergies

    Researchers have found a link between exposure to triclosan, an ingredient in antimicrobial soaps and many other consumer products, and the development of allergies and asthma.
  • Research Provides New Insights on How Hygiene Affects Asthma and Allergies

    Abstract Full Text
    JAMA. 2011; 305(14):1400-1401. doi: 10.1001/jama.2011.434